begins

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced...

Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential...